English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12190/12972 (94%)
Visitors : 1061210 Online Users : 823
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
分子與基因醫學研究所
生技與藥物研究所
生醫工程與奈米醫學研究所
免疫醫學研究中心
神經及精神醫學研究中心
細胞及系統醫學研究所
感染症與疫苗研究所
群體健康科學研究所
癌症研究所
國家環境醫學研究所
國家蚊媒傳染病防治研究中心
高齡醫學暨健康福祉研究中心
論壇
生醫資源中心
研究生培育合作學程
核心儀器設施中心
病理核心實驗室
實驗動物中心
行政管理部門
圖書館
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
國家衛生研究院 NHRI
>
Items for Author
Loading...
Category
Loading community tree, please wait....
Year
Loading year class tree, please wait....
Items for Author "Oh, DY"
Return to Browse by Author
Showing 30 items.
Collection
Date
Title
Relation
Bitstream
[陳立宗] 會議論文/會議摘要
2022-11
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
-
[陳立宗] 會議論文/會議摘要
2022-09
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
-
[陳立宗] 會議論文/會議摘要
2022-02-01
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
-
[陳立宗] 會議論文/會議摘要
2021-09
INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
-
[陳立宗] 會議論文/會議摘要
2020-09
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
-
[陳立宗] 會議論文/會議摘要
2020-09
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
-
[陳立宗] 會議論文/會議摘要
2020-02
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
-
[陳立宗] 會議論文/會議摘要
2019-10
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
-
[陳立宗] 會議論文/會議摘要
2019-02
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC)
-
[陳立宗] 會議論文/會議摘要
2019-02
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements
-
[陳立宗] 會議論文/會議摘要
2018-11
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype
-
[陳立宗] 會議論文/會議摘要
2018-10
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial
-
[陳立宗] 期刊論文
2024-08-20
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
-
[陳立宗] 期刊論文
2024-08-06
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
-
[陳立宗] 期刊論文
2024-08
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
-
[陳立宗] 期刊論文
2023-11
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
-
[陳立宗] 期刊論文
2023-01-19
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
-
[陳立宗] 期刊論文
2022-02
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
-
[陳立宗] 期刊論文
2022-01
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
-
[陳立宗] 期刊論文
2021-10
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study
-
[陳立宗] 期刊論文
2021-07
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
-
[陳立宗] 期刊論文
2020-05
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
-
[陳立宗] 期刊論文
2020-05
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
-
[陳立宗] 期刊論文
2020-02
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
-
[陳立宗] 期刊論文
2020-01
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
-
[陳立宗] 期刊論文
2018-01
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
-
[陳立宗] 期刊論文
2017-12
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
-
[陳立宗] 期刊論文
2017-10
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review
-
[陳立宗] 期刊論文
2017-08
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
-
[陳立宗] 期刊論文
2015-07
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
-
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback